|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 9 (November 1), 1998:
pp. 3035-3041
RAPID COMMUNICATION
Secretable Human Platelet-Derived Factor V Originates From the Plasma
Pool
Rodney M. Camire,
Eleanor S. Pollak,
Kenneth Kaushansky, and
Paula
B. Tracy
From the Department of Biochemistry, University of Vermont, College
of Medicine, Burlington; the Division of Hematology, The Children's
Hospital of Philadelphia, Philadelphia, PA; and the Division of
Hematology, University of Washington School of Medicine, Seattle.
Factor Va (FVa), derived from plasma or released from stimulated
platelets, is the essential protein cofactor of the prothrombinase complex. Plasma-derived factor V (FV) is synthesized by the liver, whereas the source of the platelet-derived cofactor has not been unambiguously identified. Megakaryocytes, platelet precursors, are
known to synthesize platelet proteins and to endocytose proteins from
plasma (ie, fibrinogen) and then package these proteins into  -granules. To determine which mechanism accounts for FV presence in
platelets, two patients heterozygous for FVLeiden who
underwent allogeneic transplantation from homozygous FV wild-type donors (bone marrow [BM] or liver) were studied. Patient JMW, whose
skin biopsy specimen showed heterozygous FVLeiden, received
a BM transplant from a wild-type homozygous FV donor as analyzed from
posttransplant peripheral blood cells. Patient FW, whose native liver
is heterozygous for FVLeiden, received a homozygous
wild-type FV liver. Because each individual has two distinct genetic
pools of factor V in liver and megakaryocytes, it was possible to
determine whether secretable platelet-derived FV was normal or
contained the FVLeiden mutation. Platelet-derived FVa
released from thrombin-activated platelets from a normal individual, an
individual heterozygous for the FVLeiden mutation, and the
two patients was incubated with phospholipid vesicles and activated
protein C (APC). Western blotting analyses using a monoclonal antibody
that allows distinction between platelet-derived FVa and
FVaLeiden subsequent to APC-catalyzed cleavage were then
performed. Based on the accumulation of proteolytic fragments derived
from APC-induced cleavage, analyses of platelet-derived FVa from JMW
demonstrated both normal FVa and FVaLeiden consistent with
a plasma-derived origin of the secretable platelet-derived FVa. Western
blotting analyses of the APC-cleaved platelet-derived FVa from FW
showed a wild-type phenotype, despite the presence of a
FVLeiden allele in her megakaryocyte genome, also
consistent with a plasma origin of her secretable platelet-derived FVa.
Platelets do not appear to endocytose the plasma cofactor, because a
35-hour incubation of platelet-rich plasma with 125I-factor
V showed no specific association/uptake of the radiolabeled ligand with
the platelet pellet. Collectively, these results show for the first
time that the majority of secretable platelet-derived factor V is
endocytosed by megakaryocytes from plasma and is not exclusively
synthesized by these cells, as previously believed.
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Letter in Blood Online:
-
Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation
- Jane Parker, Antonio Pagliuca, Taya Kitiyakara, Malcolm Whitehead, Nigel Heaton, John O'Grady, and Roopen Arya
Blood 2001 97: 2525-2526.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
B. Zhang, M. Spreafico, C. Zheng, A. Yang, P. Platzer, M. U. Callaghan, Z. Avci, N. Ozbek, J. Mahlangu, T. Haw, et al.
Genotype-phenotype correlation in combined deficiency of factor V and factor VIII
Blood,
June 15, 2008;
111(12):
5592 - 5600.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. T. Eitzman, R. J. Westrick, Y. Shen, P. F. Bodary, S. Gu, S. L. Manning, S. L. Dobies, and D. Ginsburg
Homozygosity for Factor V Leiden Leads to Enhanced Thrombosis and Atherosclerosis in Mice
Circulation,
April 12, 2005;
111(14):
1822 - 1825.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schulze, M. Korpal, W. Bergmeier, J. E. Italiano Jr, S. M. Wahl, and R. A. Shivdasani
Interactions between the megakaryocyte/platelet-specific {beta}1 tubulin and the secretory leukocyte protease inhibitor SLPI suggest a role for regulated proteolysis in platelet functions
Blood,
December 15, 2004;
104(13):
3949 - 3957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Washington, R. L. Schubert, L. Quigley, T. Disipio, R. Feltz, E. H. Cho, and D. W. McVicar
A TREM family member, TLT-1, is found exclusively in the {alpha}-granules of megakaryocytes and platelets
Blood,
August 15, 2004;
104(4):
1042 - 1047.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. R. Gould, J. R. Silveira, and P. B. Tracy
Unique in Vivo Modifications of Coagulation Factor V Produce a Physically and Functionally Distinct Platelet-derived Cofactor: CHARACTERIZATION OF PURIFIED PLATELET-DERIVED FACTOR V/Va
J. Biol. Chem.,
January 23, 2004;
279(4):
2383 - 2393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. V. Yarovoi, D. Kufrin, D. E. Eslin, M. A. Thornton, S. L. Haberichter, Q. Shi, H. Zhu, R. Camire, S. S. Fakharzadeh, M. A. Kowalska, et al.
Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment
Blood,
December 1, 2003;
102(12):
4006 - 4013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Berndt
On the origin of platelet factor V
Blood,
October 15, 2003;
102(8):
2712 - 2713.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. Yang, S. W. Pipe, A. Yang, and D. Ginsburg
Biosynthetic origin and functional significance of murine platelet factor V
Blood,
October 15, 2003;
102(8):
2851 - 2855.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Sun, T. L. Yang, A. Yang, X. Wang, and D. Ginsburg
The murine platelet and plasma factor V pools are biosynthetically distinct and sufficient for minimal hemostasis
Blood,
October 15, 2003;
102(8):
2856 - 2861.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Kyriakides, P. Rojnuckarin, M. A. Reidy, K. D. Hankenson, T. Papayannopoulou, K. Kaushansky, and P. Bornstein
Megakaryocytes require thrombospondin-2 for normal platelet formation and function
Blood,
May 15, 2003;
101(10):
3915 - 3923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. G. Mann and M. Kalafatis
Factor V: a combination of Dr Jekyll and Mr Hyde
Blood,
January 1, 2003;
101(1):
20 - 30.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A.F. Nicolaes and B. Dahlback
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2002;
22(4):
530 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Parker, A. Pagliuca, T. Kitiyakara, M. Whitehead, N. Heaton, J. O'Grady, and R. Arya
Discrepancy between phenotype and genotype on screening for factor V Leiden after transplantation
Blood,
April 15, 2001;
97(8):
2525 - 2526.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. W. Kamphuisen, F. R. Rosendaal, J. C. J. Eikenboom, R. Bos, and R. M. Bertina
Factor V Antigen Levels and Venous Thrombosis : Risk Profile, Interaction With Factor V Leiden, and Relation With Factor VIII Antigen Levels
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2000;
20(5):
1382 - 1386.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P.M. Hayward, Z. Song, S. Zheng, R. Fung, M. Pai, J.-M. Masse, and E. M. Cramer
Multimerin Processing by Cells With and Without Pathways for Regulated Protein Secretion
Blood,
August 15, 1999;
94(4):
1337 - 1347.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. W. Colman;, P. B. Tracy, R. M. Camire, E. S. Pollak, and K. Kaushansky
Where Does Platelet Factor V Originate?
Blood,
May 1, 1999;
93(9):
3152 - 3154.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A.F. Nicolaes and B. Dahlback
Factor V and Thrombotic Disease: Description of a Janus-Faced Protein
Arterioscler. Thromb. Vasc. Biol.,
April 1, 2002;
22(4):
530 - 538.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
